ADMA Biologics

ADMA95

High Quality

$21.50arrow_drop_up1.55%$0.33

High Quality

High Growth

ADMA95

$21.50

arrow_drop_up1.55%$0.33

High Quality

High Growth

Performance History

Key Stats
Open	$21.45
Prev. Close	$21.30
EPS	0.27
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

	LOW	HIGH
Day Range	20.68	21.46
52 Week Range	3.06	23.53

Ratios







EPS	0.27

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About ADMA Biologics (ADMA)

ADMA Biologics Inc (ADMA), a biopharmaceutical company, engages in the development and commercialization of specialty plasma-based biologics for the treatment of immune deficiencies and infectious diseases. The company's lead product, BIVIGAM, is a plasma-derived intravenous immunoglobulin (IVIG) for the treatment of primary humoral immunodeficiency. ADMA is also developing three other products, including RI-002, a plasma-derived polyclonal antibody product for the treatment of respiratory syncytial virus; Asceniv, a polyclonal antibody product candidate for the treatment of primary humoral immunodeficiency; and Nabi-HB, a plasma-derived polyclonal antibody containing a high level of antibodies to hepatitis B surface antigen for the treatment of pediatric patients. The company sells its products through distributors and direct sales. ADMA Biologics Inc was founded in 2004 and is headquartered in Ramsey, New Jersey.

ADMA Biologics Inc (ADMA) has a market capitalization of $423.83 million. The company's PEG ratio, which measures the relationship between the price/earnings ratio and the company's projected earnings growth rate, is -3.06. A PEG ratio below 1 is generally considered to be undervalued. ADMA Biologics Inc operates in the biotechnology industry, which has a trailing twelve-month P/E ratio of 23.16. ADMA's P/E ratio stands at -2.16. The company's stock has a 52-week range of $1.87 to $5.42. ADMA Biologics Inc's stock is currently trading within its day range of $4.45 to $4.60. The trading volume for ADMA Biologics Inc's stock is 1,234,567 shares.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Adam S. Grossman
Headquarters: Ramsey
Employees: 617
Exchange: NASDAQ

Keep an eye on ADMA Biologics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is ADMA Biologics 's (ADMA) price per share?

The current price per share for ADMA Biologics (ADMA) is $21.51. The stock has seen a price change of $0.33 recently, indicating a 1.56% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for ADMA Biologics (ADMA)?

For ADMA Biologics (ADMA), the 52-week high is $23.53, which is 9.41% from the current price. The 52-week low is $3.06, the current price is 602.91% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is ADMA Biologics (ADMA) a growth stock?

ADMA Biologics (ADMA) has shown an average price growth of -3.36% over the past three years. It has received a score of 95 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying ADMA Biologics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is ADMA Biologics (ADMA) stock price performance year to date (YTD)?

As of the latest data, ADMA Biologics (ADMA) has a year-to-date price change of 372.73%. Over the past month, the stock has experienced a price change of 34.77%. Over the last three months, the change has been 23.19%. Over the past six months, the figure is 124.99%. Looking at a longer horizon, the five-year price change stands at 385.53%.

help

Is ADMA Biologics (ADMA) a profitable company?

ADMA Biologics (ADMA) has a net income of -$28.24M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 34.16% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 33.08% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $258.21M, with a revenue growth rate of 67.59%, providing insight into the company's sales performance and growth. The gross profit is $88.22M. Operating income is noted at $21.63M. Furthermore, the EBITDA is $125.01M.

help

What is the market capitalization of ADMA Biologics (ADMA)?

ADMA Biologics (ADMA) has a market capitalization of $5.01B. The average daily trading volume is 21.42, indicating the stock's liquidity and investor engagement.

News

BFA Law is Investigating ADMA BIOLOGICS for Securities Fraud after Stock Plummets 20%; Contact the Firm if You Suffered Losses (Nasdaq:ADMA)

ADMA FRAUD ALERT: BFA Law Notifies ADMA Biologics Investors of Ongoing Securities Fraud Investigation after Auditor Resigns and Urges You to Contact the Firm (Nasdaq:ADMA)

ADMA INVESTIGATION UPDATE: ADMA Biologics Investors are Notified of Securities Fraud Investigation into Auditor Resignation; Contact BFA Law if You Lost Money (Nasdaq:ADMA)

ADMA Biologics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses

ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into ADMA Biologics Inc and Encourages Investors to Contact the Firm

BIOPHARMACEUTICALS

CONTRACT MANUFACTURING

Biopharmaceuticals Contract Manufacturing Industry Research 2024-2030: Biopharma Giants Increasingly Outsource to Streamline Drug Developments